News & Updates

Liporyx is proud to share that we participated in the official kick-off event of NATPRIME, a newly launched EU-funded doctoral network focused on the next generation of RNA therapeutics. The event marked the start of a multi-institutional effort to advance RNA science through interdisciplinary research and training.

Our co-founder, Alexander Cook, attended the event on behalf of Liporyx, representing our commitment to driving innovation in RNA delivery technologies. NATPRIME brings together leading academic and industry partners across Europe, including our collaborator Prof. Jan van Hest of Eindhoven University of Technology, who is involved as a co-coordinator of the network.

As contributors to NATPRIME, Liporyx will support doctoral training and contribute scientific expertise in the development of advanced lipid-based delivery systems. This collaboration underscores our mission to translate cutting-edge RNA research into meaningful therapeutic solutions.

We're excited to be part of this ambitious program and look forward to the discoveries and partnerships it will foster.

Link

We're excited to announce that Liporyx has been awarded a Level 1 grant from the Biotech Booster program, part of the Dutch National Growth Fund initiative. This milestone grant provides crucial support as we take the next steps in our development journey. The grant will enable us to further validate our RNA delivery technology in preclinical models, a key step in demonstrating its potential for therapeutic application.

The Biotech Booster program supports high-potential biotech ventures in the Netherlands by accelerating early-stage innovation and helping research-based startups move toward commercial readiness. This non-dilutive funding is especially valuable in helping us build a strong scientific and operational foundation. We're proud to be recognized as part of this initiative and excited to grow alongside the thriving Dutch life sciences ecosystem.

This support not only strengthens our position as an emerging RNA therapeutics company but also moves us closer to future private investment opportunities and the realization of our mission: to transform RNA delivery with novel, effective, and clinically viable solutions.

Stay tuned for updates as we progress with our preclinical validation work and lay the groundwork for the next phase of our journey.

Link

Our research team has developed a novel lipid-polymer hybrid system that significantly improves RNA delivery efficiency. The PCT patent application for our novel lipid-polymer hybrid system designed to significantly enhance the delivery of RNA therapeutics was recently published. The study demonstrates enhanced cellular uptake and reduced toxicity compared to conventional delivery methods. This marks a major milestone in the development and protection of our proprietary technology.

The lipid-like polymer technology forms a cornerstone of our ongoing preclinical development efforts and supports our broader vision to enable next-generation RNA immunotherapies.